Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 20/20 | 0.85 |
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22779908 | 0.92 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL22779880 | 0.91 | PDCD1 (0.89) | PDCD1CD274 | |
| SCHEMBL22933647 | 0.91 | PDCD1 (0.89) | PDCD1CD274 | |
| SCHEMBL29558287 | 0.91 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL24659910 | 0.91 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL24660118 | 0.91 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL22779974 | 0.91 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL22779978 | 0.91 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL22779909 | 0.91 | PDCD1 (0.89) | PDCD1CD274 | |
| SCHEMBL22769826 | 0.90 | PDCD1 (1.00) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750887-B1 | BIARYL DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATION FOR THE TREATMENT OF PD-1/PD-L1 SIGNAL PATHWAY-MEDIATED DISEASES | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-11459339-B2 | Biaryl derivative, preparation method thereof and pharmaceutical application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-10-04 | — | — | US | disclosed |
| US-20210032270-A1 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3750887-A1 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750887-A1 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032270-A1 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | PDCD1, PDCD1LG2, CD274 | PDCD1 1/4885CD274 3/4885 |
| US-11459339-B2 | Biaryl derivative, preparation method thereof and pharmaceutical application thereof | PDCD1, PDCD1LG2, CD274 | PDCD1 1/4885CD274 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.